Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Everyone has begun their push toward the summit of Annapurna, but Imagine Nepal leader Mingma G says he has never seen the ...

Audrey Cathey always dreamed of continuing her softball career in the SEC and a "blue-collar" Missouri program stood tall ...